Edition:
United States

CEL-SCI Corp (CVM.A)

CVM.A on American Stock Exchange

1.69USD
21 Jun 2017
Change (% chg)

$-0.01 (-0.59%)
Prev Close
$1.70
Open
$1.66
Day's High
$1.72
Day's Low
$1.64
Volume
14,186
Avg. Vol
14,046
52-wk High
$13.55
52-wk Low
$1.46

CVM.A

Chart for CVM.A

About

CEL-SCI Corporation is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company is focused on activating the immune system to fight cancer and infectious diseases. It operates through the segment of research and development of certain drugs and... (more)
No analyst recommendations are available for CVM.A.

Overall

Beta: -1.62
Market Cap(Mil.): $15.54
Shares Outstanding(Mil.): 9.19
Dividend: --
Yield (%): --

Financials

  CVM.A Industry Sector
P/E (TTM): -- 244.33 18.98
EPS (TTM): -1.55 -- --
ROI: -183.07 -7.97 -5.09
ROE: -- -9.96 -4.32

BRIEF-Cel-Sci reports reverse stock split

* Cel-Sci Corp - Cel-Sci expects split to be implemented on June 15, 2017

Jun 12 2017

BRIEF-CEL-SCI submits FDA response for its phase 3 head and neck cancer trial

* Cel-SCI submits FDA response for its phase 3 head and neck cancer trial

Jun 05 2017

BRIEF-Cel-Sci Q2 loss per share $0.05

* Cel-Sci Corporation reports second quarter fiscal year 2017 financial results

May 10 2017

BRIEF-Cel-Sci announces $1.51 million registered direct offering

* Cel-Sci - entered definitive agreement with one institutional investor for offering of shares of stock with proceeds of about $1.51 million in direct offering

May 01 2017

BRIEF-Cel-Sci Corp scientist presents new findings for rheumatoid arthritis treatment vaccine

* Cel-Sci Corp - Cel-Sci scientist presents new findings for rheumatoid arthritis treatment vaccine

Feb 21 2017

BRIEF-CEL-SCI announces $1.0 million registered direct offering

* Intends to use net proceeds from offering for phase 3 clinical study Source text for Eikon: Further company coverage:

Feb 17 2017

More From Around the Web

Earnings vs. Estimates